A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
Public ClinicalTrials.gov record NCT04873362. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase III, two-arm, randomized, double-blind placebo-controlled study in participants with HER2-positive primary breast cancer who have received preoperative chemotherapy and HER2-directed therapy, including trastuzumab followed by surgery, with a finding of residual invasive disease in the breast and/or axillary lymph nodes. As of June 4, 2024, this study is no longer accepting any newly screened participants.
Study identification
- NCT ID
- NCT04873362
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,188 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 4, 2021 (Actual)
- Primary completion
- Mar 31, 2027 (Estimated)
- Completion
- Oct 2, 2034 (Estimated)
- Last update posted
- Sep 3, 2026
2021 – 2034
United States locations
- U.S. sites
- 22
- U.S. states
- 13
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alabama Oncology | Birmingham | Alabama | 35205 | — |
| Roy and Patricia Disney Family Cancer Center- Providence Saint Joseph Medical Center | Buena | California | 91505 | — |
| UCLA Medical Center | Santa Monica | California | 90404 | — |
| Innovation Clinical Research Institute | Whittier | California | 90603 | — |
| Florida Cancer Specialists | West Palm Beach | Florida | 33401 | — |
| Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital | Carrollton | Georgia | 30117 | — |
| University of Iowa | Iowa City | Iowa | 52242-1086 | — |
| New England Cancer Specialists | Westbrook | Maine | 04092 | — |
| The Valley Hospital | Paramus | New Jersey | 07652 | — |
| Levine Cancer Institute | Charlotte | North Carolina | 28204 | — |
| Abramson Cancer Center; Univ of Pennsylvania; Clinical Research Unit | Philadelphia | Pennsylvania | 19106 | — |
| The West Clinic | Germantown | Tennessee | 38138 | — |
| Thompson Cancer Survival Center | Knoxville | Tennessee | 37916-2305 | — |
| Mays Cancer Center at UT Health San Antonio MD Anderson Cancer | San Antonio | Texas | 78229 | — |
| Hematology Oncology Associates of Fredericksburg, Inc. | Fredericksburg | Virginia | 22408 | — |
| Virginia Oncology Associates - New Port News | Newport News | Virginia | 23606 | — |
| Virginia Oncology Associates | Norfolk | Virginia | 23502 | — |
| Virginia Cancer Institute | Richmond | Virginia | 23229 | — |
| Virginia Oncology Associates - Virginia Beach | Virginia Beach | Virginia | 23456 | — |
| Providence Regional Cancer Partnership | Everett | Washington | 98201 | — |
| Kadlec Clinic Hematology and Oncology | Kennewick | Washington | 99336-7774 | — |
| Northwest Medical Specialties | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 216 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04873362, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 3, 2026 · Synced Sep 30, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04873362 live on ClinicalTrials.gov.